Ng2 Glia (Oligodendrocyte Precursor Cells) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
NG2 Glia, also known as Oligodendrocyte Precursor Cells (OPCs), are a distinct population of glial cells in the central nervous system that serve as progenitors for oligodendrocytes. These cells are widely distributed throughout both gray and white matter, representing approximately 5-10% of all cells in the adult mammalian brain[1]. NG2 glia are characterized by their expression of the chondroitin sulfate proteoglycan NG2 (encoded by CSPG4) and the platelet-derived growth factor receptor alpha (PDGFRα, encoded by PDGFRA)[2].
| Cell Type Information | |
|---|---|
| Cell Type | NG2 Glia / Oligodendrocyte Precursor Cells |
| Abbreviation | OPCs |
| Location | Throughout CNS gray and white matter |
| Key Markers | NG2 (CSPG4), PDGFRα (PDGFRA), Olig2, Sox10 |
| Function | Myelin progenitor cells, synaptic partners |
NG2 glia have a distinctive morphology with multiple branched processes that extend from a small to medium-sized cell body (10-15 μm in diameter). Their processes form extensive networks throughout the neuropil, allowing them to contact multiple neurons and axons[3].
NG2 glia express a characteristic set of molecular markers that distinguish them from other glial cell types[4]:
| Marker | Gene | Function |
|---|---|---|
| NG2 | CSPG4 | Chondroitin sulfate proteoglycan |
| PDGFRα | PDGFRA | Growth factor receptor |
| Olig2 | OLIG2 | Transcription factor |
| Sox10 | SOX10 | Transcription factor |
| NKX2.2 | NKX2-2 | Transcription factor |
| CC1 | APC | Cell cycle regulation |
NG2 glia are the primary source of new oligodendrocytes in the adult brain. Under normal conditions, these cells continuously proliferate and differentiate into mature oligodendrocytes, contributing to ongoing myelin maintenance and repair[5]. Adult NG2 glia retain proliferative capacity and can respond to demyelination by mounting a regenerative response.
NG2 glia receive direct synaptic input from neurons, forming neuron-glia synapses[6]. These synapses use glutamatergic and GABAergic neurotransmission, suggesting bidirectional communication:
NG2 glia provide metabolic support to axons through lactate shuttling, similar to astrocytes[7]. They express monocarboxylate transporters (MCT1, MCT4) that allow them to export lactate to axons for energy metabolism.
NG2 glia arise from embryonic neural progenitor cells in the ventricular zone[8]. Their development proceeds through distinct stages:
NG2 glia are significantly affected in MS lesions[9]. The progressive loss of NG2 glia and their inability to effectively remyelinate lesions contributes to chronic demyelination. In MS:
In ALS, NG2 glia exhibit abnormal behavior[10]:
NG2 glia show changes in AD[11]:
In PD models, NG2 glia[12]:
NG2 glia are particularly vulnerable in periventricular leukomalacia (PVL)[13]:
Single-cell transcriptomic studies have characterized NG2 glia populations[14]:
NG2 glia are key targets for remyelination therapies[15]:
NG2 protein in cerebrospinal fluid may serve as a biomarker[16]:
| Target | Approach | Status |
|---|---|---|
| PDGFRα | Agonists for proliferation | Preclinical |
| Lingo-1 | Antagonist to promote differentiation | Phase 2 trials |
| OPC fate | Transcription factor modulators | Research |
The study of Ng2 Glia (Oligodendrocyte Precursor Cells) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Nishiyama A, et al. NG2 cells in the CNS: from development to function. J Anat. 2021;239(1):16-36. PMID:33219623. ↩︎
Stallcup WB, Beasley L. Bipotential glial cells are distinct from astrocytes and oligodendrocytes. J Neurosci. 1987;7(8):2737-2752. PMID:3302135. ↩︎
Buttarelli FR, et al. The relationship between NG2 cells and astrocytes in the rat brain. J Neurocytol. 2004;33(3):345-355. PMID:15475690. ↩︎
Karram K, et al. NG2 cells in the CNS: characterization and therapeutic potential. Brain Res Rev. 2008;57(2):298-307. PMID:18042384. ↩︎
Rivers LE, et al. PDGFRA/NG2 glia generate myelinating oligodendrocytes and piriform projection neurons in adult mice. Nat Neurosci. 2008;11(12):1392-1401. PMID:19030186. ↩︎
Bergles DE, et al. Glutamatergic synapses on oligodendrocyte precursor cells in the hippocampus. Nature. 2000;405(6783):187-192. PMID:10821275. ↩︎
Rinholm JE, et al. Regulation of oligodendrocyte development and myelination by lactate. J Neurosci. 2011;31(2):538-548. PMID:21228163. ↩︎
Zhu X, et al. NG2 cells in development and disease. Glia. 2020;68(12):2391-2408. PMID:32678910. ↩︎
Chang A, et al. NG2 immunoreactive oligodendrocyte processes in normal human white matter. Ann Neurol. 2002;51(4):422-429. PMID:11921048. ↩︎
Ferraiuolo L, et al. Dysregulation of astrocyte-oligodendrocyte progenitor cell cross-talk in ALS. Brain. 2021;144(8):2312-2325. PMID:33880521. ↩︎
Araque J, et al. NG2 glia alterations in Alzheimer's disease. J Neurosci Res. 2019;97(9):1084-1097. PMID:31050178. ↩︎
McGinn A, et al. Oligodendrocyte precursor cells in Parkinson's disease. Mov Disord. 2020;35(12):2132-2142. PMID:32892345. ↩︎
Volpe JJ, et al. Pathogenesis of periventricular leukomalacia: role of the perinatal cerebral white matter injury. J Pediatr. 2011;159(2):197-201. PMID:21492618. ↩︎
Marques S, et al. Oligodendrocyte heterogeneity in the mouse forebrain revealed by single-cell RNA sequencing. Nat Neurosci. 2018;21(1):103-115. PMID:29203898. ↩︎
Plemel JR, et al. Remyelination therapies in multiple sclerosis. Nat Rev Neurol. 2021;17(12):755-768. PMID:34795444. ↩︎
LORENZETTI V, et al. Chondroitin sulfate proteoglycans in cerebrospinal fluid. Neurology. 2009;73(18):1484-1490. PMID:19884571. ↩︎